Select a medication above to begin.
Aucatzyl
obecabtagene autoleucel
Black Box Warnings .
Cytokine Release Syndrome
do not admin. if active infection or inflammatory disorders; ensure providers have immediate access to meds, resuscitative equipment to manage CRS before admin; monitor pts daily for at least 14 days after 1st infusion at certified healthcare facility, and monitor s/sx for at least 4wk after each infusion w/in proximity of certified healthcare facility; counsel pts on s/sx and to seek immediate medical attention if they occur at any time
Neurological Toxicities
immune effector cell-associated neurotoxicity syndrome, incl. fatal or life-threatening, occurred, incl. concurrently w/ CRS or after CRS resolution; ensure providers have immediate access to meds, resuscitative equipment to manage neurologic toxicities before admin; provide supportive care and/or corticosteroids as needed; monitor pts at least daily x14 days after 1st infusion at certified healthcare facility, and monitor s/sx for at least 4wk after each infusion w/in proximity of certified healthcare facility; counsel pts on s/sx and to seek immediate medical attention if they occur at any time
Secondary Hematological Malignancies
incl. T-cell malignancies, have occurred; monitor life-long; contact Autolus Therapeutics at 1-855-288-5227 to report malignancy occurrence and obtain instructions on pts sample collection
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, prophylactic antimicrobials, and dosing
B-cell precursor ALL, relapsed or refractory
- [bone marrow blast <20%]
- Dose: 100 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg/dose IV x1 on day 1, then 310 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg/dose IV x1 on day 10; Start: 3 days after completing lymphodepleting combo chemo cyclophosphamide + fludarabine
- [bone marrow blast >20% or biopsy results inconclusive]
- Dose: 10 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg/dose IV x1 on day 1, then 400 x10^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg/dose IV x1 on day 10; Start: 3 days after completing lymphodepleting combo chemo cyclophosphamide + fludarabine
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- pregnancy
- infection, active
- inflammatory disorder
- avoid: blood donation indefinitely
- avoid: organ donation indefinitely
- avoid: tissue donation indefinitely
- avoid: cell donation indefinitely
- caution: hypersensitivity to DMSO
- caution: female pts of reproductive potential
Drug Interactions .
Overview
obecabtagene autoleucel
CAR T cell immunotherapy
- immunomodulatory effects (other)
- immunosuppressive oncologic agent
- lowers seizure threshold
- myelosuppressive oncologic agent
Contraindicated
- BCG live intravesical
- talimogene laherparepvec
Avoid/Use Alternative
- abrocitinib
- adenovirus vaccine, live
- aldesleukin
- amifampridine
- anifrolumab
- anti-thymocyte globulin
- azathioprine
- basiliximab
- belatacept
- betamethasone
- budesonide
- chikungunya vaccine, live
- chloramphenicol
- cholera vaccine, live
- cladribine oral
- cortisone
- cyclosporine
- deferiprone
- deflazacort
- dengue vaccine, live
- dexamethasone
- dexrazoxane
- etrasimod
- everolimus
- fexinidazole
- fludrocortisone
- ganciclovir
- hydrocortisone
- influenza nasal vaccine, live
- iohexol
- lymphocyte immune globulin, anti-thymocyte globulin
- measles/mumps/rubella vaccine, live
- methylprednisolone
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- palifermin
- penicillamine
- pimecrolimus topical
- prednisolone
- prednisone
- primaquine
- radium Ra 223 dichloride
- ritlecitinib
- ropeginterferon alfa-2b
- rotavirus vaccine, live
- ruxolitinib topical
- sirolimus
- smallpox vaccine, live
- tacrolimus
- triamcinolone
- typhoid vaccine, live
- valganciclovir
- vamorolone
- varicella vaccine, live
- voclosporin
- yellow fever vaccine, live
Monitor/Modify Tx
- albendazole
- alemtuzumab
- allopurinol
- anthrax vaccine
- asenapine
- atidarsagene autotemcel
- auranofin
- balsalazide
- baricitinib
- benznidazole
- betibeglogene autotemcel
- bupropion
- chikungunya vaccine
- cidofovir
- clozapine
- colchicine
- COVID-19 vaccine
- cyclophosphamide
- dapsone
- deferasirox
- deuruxolitinib
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- ebola vaccine, live
- efbemalenograstim alfa
- eflapegrastim (G-CSF)
- elivaldogene autotemcel
- exagamglogene autotemcel
- filgrastim (G-CSF)
- flucytosine
- fluphenazine
- foscarnet
- fostamatinib
- givinostat
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydroxychloroquine
- hydroxyurea
- iloperidone
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- iopamidol
- Japanese encephalitis vaccine
- leflunomide
- linezolid
- lonafarnib
- lovotibeglogene autotemcel
- lumateperone
- meningococcal vaccine
- mercaptopurine
- mesalamine
- mesalamine rectal
- methotrexate
- olsalazine
- pegfilgrastim (G-CSF)
- peginterferon alfa 2a
- peginterferon beta 1a
- pentamidine
- pneumococcal vaccine
- poliovirus vaccine
- proguanil
- pyrimethamine
- rabies vaccine
- respiratory syncytial virus vaccine
- ribavirin
- rifabutin
- rituximab
- sargramostim (GM-CSF)
- sarilumab
- satralizumab
- sipuleucel-T
- smallpox/mpox vaccine, live
- stiripentol
- succimer
- sulfasalazine
- teplizumab
- teriflunomide
- thalidomide
- tick-borne encephalitis vaccine
- tocilizumab
- tofacitinib
- trimethoprim
- typhoid vaccine
- upadacitinib
- valproic acid
- zidovudine
- zoster vaccine, recombinant
Caution Advised
- abatacept
- acetazolamide
- adalimumab
- anakinra
- avacopan
- beclomethasone inhaled
- beclomethasone nasal
- belimumab
- bimekizumab
- brivaracetam
- brodalumab
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- canakinumab
- cannabidiol
- carbamazepine
- cenobamate
- certolizumab pegol
- chlorambucil
- clobazam
- clobetasol ophthalmic
- clomipramine
- clonazepam
- clorazepate
- corticotropin
- crovalimab
- danicopan
- deucravacitinib
- dexamethasone ophthalmic
- diazepam
- difluprednate ophthalmic
- dimethyl fumarate
- diroximel fumarate
- dupilumab
- eculizumab
- efgartigimod alfa
- emapalumab
- eslicarbazepine acetate
- etanercept
- ethosuximide
- felbamate
- fenfluramine
- fingolimod
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fosphenytoin
- gabapentin
- ganaxolone
- golimumab
- guselkumab
- hydrocortisone ophthalmic
- inebilizumab
- infliximab
- iptacopan
- ixekizumab
- lacosamide
- lamotrigine
- lebrikizumab
- levetiracetam
- lindane topical
- lorazepam
- loteprednol ophthalmic
- magnesium citrate
- methsuximide
- midazolam
- mirikizumab
- mitoxantrone
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- nadofaragene firadenovec intravesical
- ocrelizumab
- ofatumumab
- oxcarbazepine
- ozanimod
- pegcetacoplan
- perampanel
- phenobarbital
- phenytoin
- polyethylene glycol
- polyethylene glycol/electrolytes
- ponesimod
- pozelimab
- prednisolone ophthalmic
- pregabalin
- primidone
- promethazine
- ravulizumab
- rilonacept
- risankizumab
- rozanolixizumab
- rufinamide
- secukinumab
- siltuximab
- siponimod
- sodium picosulfate
- spesolimab
- sulfate bowel prep
- sutimlimab
- tezepelumab
- tiagabine
- tildrakizumab
- topiramate
- tralokinumab
- tramadol
- treosulfan
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vedolizumab
- vigabatrin
- vilobelimab
- zilucoplan
- zonisamide
Adverse Reactions .
Serious Reactions
- cytokine release syndrome
- hypotension, severe
- fever
- hypoxia
- cardiac failure
- arrhythmia
- respiratory failure
- ARDS
- neurotoxicity, severe
- immune effector cell-assoc. neurotoxicity syndrome
- encephalopathy
- seizures
- hypersensitivity rxn, severe
- anaphylaxis
- infection, serious
- febrile neutropenia
- viral reactivation
- neutropenia, incl. prolonged
- thrombocytopenia, incl. prolonged
- anemia
- lymphopenia
- hypogammaglobulinemia
- hemophagocytic lymphohistiocytosis
- macrophage activation syndrome
- thrombosis
- hemorrhage
- coagulopathy
- ascites
- secondary malignancy
- T-cell malignancy
- chimeric antigen receptor (CAR)-positive lymphoma
Common Reactions
- cytokine release syndrome
- fever
- neutropenia, incl. prolonged
- neurotoxicity
- thrombocytopenia, incl. prolonged
- infection
- musculoskeletal pain
- nausea
- febrile neutropenia
- diarrhea
- hypotension
- immune effector cell-assoc. neurotoxicity syndrome
- pain
- headache
- fatigue
- encephalopathy
- hemorrhage
- vomiting
- rash
- abdominal pain
- dizziness
- cough
- hypoxia
- appetite decr.
- tachycardia
- edema
- constipation
- rigors
- weight decr.
- coagulopathy
- hypogammaglobulinemia
- lymphocytopenia
- anemia
Safety/Monitoring .
Monitoring Parameters
screening for HBV, HCV, HIV before leukapheresis; pregnancy test at baseline; s/sx infection before and after infusion; CBC, IgG levels after infusion; s/sx cytokine release syndrome, neurological toxicities at least daily x14 days after 1st infusion at certified healthcare facility, and for at least 4wk after each infusion w/in proximity of certified healthcare facility
Pregnancy/Lactation .
Pregnancy
Clinical Summary
avoid use during pregnancy; no human or animal data available; possible risk of B-cell lymphocytopenia and hypogammaglobulinemia based on drug's mechanism of action
Individuals of Reproductive Potential
obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during and after tx in female pts
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: unknown; Half-life: unknown
Subclass: Immunotherapy, CAR T-Cells ; Immunotherapy, CD19 Inhibitors
Mechanism of Action
binds to CD19-expressing cells via chimeric antigen receptor (CAR)-positive autologous T-cells, inducing T-cell expansion, activation, and proliferation, and eliminating CD19-expressing cells
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.